Female hormone therapy associated with risk of intracranial hemorrhage in patients with cerebral spongiform malformations

Published Date: 04 Mar 2023

Germany: A recent study shows that female hormone therapy increases the risk of cerebral hemorrhage in patients with cerebral hemorrhage.

Read Full News

Latest News

Professional Corner: What’s New in Primary Care?

A new survey examines young adults’ use of primary care, Nebraska receives funding for rural training, and Trinity Health expands services in West Michigan.

Maternal BMI and Birth Length Tied to Dermatitis Risk

A higher maternal prepregnancy BMI and greater birth length are associated with an elevated risk for atopic dermatitis in offspring by 3 years of age, new research shows.

Diabetologists On the Rise as Disease Overwhelms Practices

The launch of the American College of Diabetology has helped dozens of physicians become board-certified, with more on the way.

CMA Funds Program to HELP International Physicians Practice

A new commitment will support a program that familiarizes internationally trained physicians with medical English and the Canadian healthcare system.

Doctors Fired After Unionizing Win Settlement From Employer

Peak Vista Community Health Centers will pay $1.2 million to four physicians and a nurse practitioner after a decision by the National Labor Relations Board.

Todays Updates

IZAR-1: Sonelokimab Meets Phase 3 End Points for PsA

IZAR-1: Sonelokimab Meets Phase 3 End Points for PsA

What 2 Seasons of Arexvy Data Reveal About RSV-Related Risk Reduction Ann Falsey, MD

Two-season real-world data show Arexvy reduces RSV-related MACE and COPD and asthma exacerbations in adults 60 and older, Ann Falsey, MD, says.

Dupilumab Outperforms Omalizumab for Asthma Remission in Phase 4 EVEREST Guy Brusselle, MD, PhD

Guy Brusselle, MD, PhD, says that 64% of dupilumab-treated patients met composite asthma clinical remission criteria at week 24 versus 40.5% with omalizumab.

What The FDA Psychedelic Hearing Means for Psychiatrists

What The FDA Psychedelic Hearing Means for Psychiatrists

Phase 4 OCTAGON Trial to Test Rapid Steroid Taper With Ravulizumab Marco Meglio

A new phase 4 trial, OCTAGON, will test a rapid, predefined corticosteroid-tapering schedule in patients with generalized myasthenia gravis treated with ravulizumab.

Phase 4 Study Evaluates Transition From IVIG to Subcutaneous Efgartigimod in CIDP Louie Pasculli

A phase 4 study is evaluating whether adults with chronic inflammatory demyelinating polyneuropathy can transition from intravenous immunoglobulin to subcutaneous efgartigimod PH20 without first experiencing disease worsening.

Phase 4 Study Shows Stable Motor Function in Adults With SMA on Risdiplam Isabella Ciccone, MPH

Real-world 12‑month results from WeSMA, a phase 4 study, showed that oral risdiplam is well tolerated in adults with SMA, with stable motor function and consistent safety findings.

Todays Updates

IZAR-1: Sonelokimab Meets Phase 3 End Points for PsA

IZAR-1: Sonelokimab Meets Phase 3 End Points for PsA

What 2 Seasons of Arexvy Data Reveal About RSV-Related Risk Reduction Ann Falsey, MD

Two-season real-world data show Arexvy reduces RSV-related MACE and COPD and asthma exacerbations in adults 60 and older, Ann Falsey, MD, says.

Dupilumab Outperforms Omalizumab for Asthma Remission in Phase 4 EVEREST Guy Brusselle, MD, PhD

Guy Brusselle, MD, PhD, says that 64% of dupilumab-treated patients met composite asthma clinical remission criteria at week 24 versus 40.5% with omalizumab.

What The FDA Psychedelic Hearing Means for Psychiatrists

What The FDA Psychedelic Hearing Means for Psychiatrists

Phase 4 OCTAGON Trial to Test Rapid Steroid Taper With Ravulizumab Marco Meglio

A new phase 4 trial, OCTAGON, will test a rapid, predefined corticosteroid-tapering schedule in patients with generalized myasthenia gravis treated with ravulizumab.

Phase 4 Study Evaluates Transition From IVIG to Subcutaneous Efgartigimod in CIDP Louie Pasculli

A phase 4 study is evaluating whether adults with chronic inflammatory demyelinating polyneuropathy can transition from intravenous immunoglobulin to subcutaneous efgartigimod PH20 without first experiencing disease worsening.

Phase 4 Study Shows Stable Motor Function in Adults With SMA on Risdiplam Isabella Ciccone, MPH

Real-world 12‑month results from WeSMA, a phase 4 study, showed that oral risdiplam is well tolerated in adults with SMA, with stable motor function and consistent safety findings.

Latest News

A new survey examines young adults’ use of primary care, Nebraska receives funding for rural training, and Trinity Health expands services in West Michigan.

A higher maternal prepregnancy BMI and greater birth length are associated with an elevated risk for atopic dermatitis in offspring by 3 years of age, new research shows.

The launch of the American College of Diabetology has helped dozens of physicians become board-certified, with more on the way.

A new commitment will support a program that familiarizes internationally trained physicians with medical English and the Canadian healthcare system.

Peak Vista Community Health Centers will pay $1.2 million to four physicians and a nurse practitioner after a decision by the National Labor Relations Board.

News All Time

The CDSCO panel approves AstraZeneca's study of the antihypertensive medication baxdrostat.

New Delhi: Under the Central Drug Standard Control, the Subject Expert Committee (SEC) has granted approval to AstraZeneca, a major pharmaceutical company.

Check the facts: Posts on social media asserting that biology is not necessary for NEET UG are false.

posts on social media asserting that biology coursework is no longer necessary for those aspiring to become doctors in order to take the National Eligibility-cum-Entrance Test.

Kerala High Court orders Time-Bound Immediate Investigation into Unnecessary Embarrassment of Doctors from Delayed Medical Negligence Probe.

New Delhi: The Kerala High Court on Monday highlighted the possibility that physicians who are innocent could be subjected to needless humiliation should the investigation delay.

Eugene A. Woods joins the board of directors at JnJ.

Johnson and Johnson has announced in New Brunswick that Eugene A. The new CEO of Advocate Health is Woods, MBA, MHA.

Only 30% of doctors' families who passed away from COVID-19 received compensation up until 2023:RTI.

In response to a Right to Information query asking about the total Covid martyrs compensated under the Pradhan Mantri Garib Kalyan Package (PMGKP),.

Medical students from Manipur who have been displaced are able to pursue their education via online or hybrid modes thanks to NMC.

The Undergraduate Medical Education Board (UGMEB) of the National Medical Commission (NMC) has permitted displaced parties, providing a remarkable reprieve.

Incorporate the Ankle Brachial Index examination to rule out peripheral artery disease: A CDSCO Panel Notifies Lupin Regarding Denosumab PK/PD Research.

New Delhi: Under the Central Drug Standard Control, the Subject Expert Committee (SEC) has approved the drug major Lupin.

Delhi High Court: MCI sanctions cannot be used as a yardstick for determining a doctor's shortcomings, flaws, or insufficiency.

New Delhi: The Delhi High Court recently declared that the punishment awarded by the MCI, which is now the National Medical Commission (NMC), could not be an.

As per JAMA, Prone Positioning Has No Effect on the Length of ECMO Weaning in Covid Patients with Severe ARDS.

According to Matthieu Schmidt and colleagues, a randomized clinical trial examined the effects of prone positioning on patients suffering from severe acute respiratory distress.

Rituximab and glucocorticoids in Wegener's Granulomatosis: A PMS Study Report approved by the CDSCO Panel.

New Delhi: The Central Drug Standard Control Organization (CDSCO)'s Subject Expert Committee (SEC) has authorized a post-marketing.

The manufacture and marketing of Azelnidipine and Metoprolol FDC tablets has been approved by the CDSCO Panel for Akum Pharmaceutical.

New Delhi: The Subject Expert Committee (SEC) operating under the Central Drug Standard has given the go-ahead to the pharmaceutical giant Akum Pharmaceuticals.

Health Bulletin / November 30, 2023.

Following a spike in respiratory cases, Uttarakhand and Karnataka are on alert due to a pneumonia outbreak in China. These are the top health stories of the day.

The MP government issues a directive to Yatharth Hospital to assume control of the Ramraja Hospital grounds.

MP: As a result of an order from the Commissionerate of Sagar Sambhag, Madhya, Yatharth Hospital experienced significant trouble yesterday.

Check Your Information: Media reports asserting that biology is not necessary for NEET UG are false.

New Delhi: Posts on social media assert that biology coursework is no longer necessary for applicants to the National Exam to pursue careers in medicine.

The deadline to submit course preferences, willingness to work, and fee for the special straw vacancy round for PG medical seats in Puducherry is today.

The Centralized Admission Committee (CENTAC) in Puducherry has released a notification concerning the special stray vacancy round for three open NEET PG seats.

A radiologist found guilty of violating the PC PNDT Act received a two-year rigorous prison sentence.

A session court in Jabalpur has found a DMRD doctor guilty of a heinous violation of the Pre-Conception and Pre-Natal Diagnostic Techniques (PCPNDT) Act.

Recommended News For You

Skinny melanoma incidence is associated with vitamin D deficiency.

FAPI PET/CT enhances the staging of recently discovered breast cancer, according to comparative analysis.

Early-Onset Colorectal Cancer in Male Veterans is Predicted by Risk Factors.

New drug combination shows particularly good results in patients with HPV-negative head and neck cancer

Taking vitamin D daily decreased cancer mortality, according to a study.

Scientists pioneer noninvasive 3D imaging to enhance skin cancer management

Kate Middleton Gives Cancer Update

Recommended Articles For You

Robotic Intratumoral Resection for Organ Preservation: Advances, Evidence, and Clinical Implications 

From Bruises to Blood Clots: Everything You Need to Know about Hematoma  

Extracellular Vesicle Markers of Platelet Activation: Clinical Relevance and Emerging Insights 

Understanding Evans Syndrome: Causes, Symptoms, and Treatment Options  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

According to JAMA, 5 alpha-reductase inhibitors are not significantly linked to prostate cancer mortality.

2.

As EGFR internalization is decreased, BUB1 controls EGFR signaling.

3.

New therapeutic strategies raised to prevent and resist metastasis in lymph nodes of breast cancer

4.

An understudied type of breast cancer poses a lurking threat

5.

More men with prostate cancer are avoiding unnecessary surgery

1.

Evidence-Based Approaches in Hematology for Modern Medicine

2.

The Importance of Having a Quick and Effective Heparin Antidote 

3.

Cardio-Oncology: Managing Heart Failure in Survivors of Cancer

4.

A Visual Journey Through Penile Cancer: Examining the Impact of Photos

5.

Targeted Therapies for Breast Cancer: What’s New?

1.

International Cancer Conference

2.

Asian Symposium on Advancement in Hematology and Oncology (ASAHO)

3.

International Cancer Conference

1.

Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases

2.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion

3.

From Relapse to Remission Mapping the Treatment Journey in Adult R R B Cell ALL The Critical Goal of MRD

4.

Importance of Cancer Screening and Early Detection

5.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot